The content on this site is intended for healthcare professionals only
Prof Sweeney discusses the CHAARTED trial (ChemoHormonal Therapy versus Androgen Ablation Randomised Trial for Extensive Disease in Prostate Cancer) and its implications for the treatment of prostate cancer at ESMO 2014.
From the same symposium:
Understanding PC heterogeneity to guide treatment choices
Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival
ASCO GU 2026: Updates in metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
Looking at real world evidence on PSA testing in prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer
Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men
Single intensive screening intervention using PSA and Stockholm3 in combination might reduce prostate cancer mortality
Spindle cell lesions of the breast
